AR034557A1 - Derivados de (2-azabiclo[2.2.1]hept-7-il)metanol como agonistas de receptores nicotinicos de acetilcolina - Google Patents
Derivados de (2-azabiclo[2.2.1]hept-7-il)metanol como agonistas de receptores nicotinicos de acetilcolinaInfo
- Publication number
- AR034557A1 AR034557A1 ARP010104304A ARP010104304A AR034557A1 AR 034557 A1 AR034557 A1 AR 034557A1 AR P010104304 A ARP010104304 A AR P010104304A AR P010104304 A ARP010104304 A AR P010104304A AR 034557 A1 AR034557 A1 AR 034557A1
- Authority
- AR
- Argentina
- Prior art keywords
- groups
- substances
- substituted
- unsubstituted
- group
- Prior art date
Links
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 title abstract 2
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 title abstract 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 title 3
- 239000000126 substance Substances 0.000 abstract 5
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000172 C5-C10 aryl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000001190 organyl group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000003441 thioacyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Abstract
Sustancias de la fórmula general (1) donde: la línea punteada representa un enlace doble opcional; X se selecciona del grupo formado por NH, NR4, O y S; R1 se selecciona del grupo formado por hidrógeno, grupo alquilo C1-10 lineales y ramificados, sustituidos e insustituidos, grupos arilo C5-10 sustituidos e insustituidos, grupos heteroarilo C4-10 sustituidos e insustituidos, grupos acilo, tioacilo, carbonilcarboxi, carbamoilo N-organil sustituidos y organosulfonilo; R2, R3 y R4 se seleccionan independientemente entre sí del grupo formado por grupos alquilo C1-10, arilo C5-12 y heteroarilo C4-12, donde estos grupos son insustituidos o presentan uno o varios sustituyentes que se seleccionan independientemente entre sí del grupo formado por halógenos, grupos alcoxi, ariloxi, nitro, alcoxicarbonilo C1-5, alquilo o acilo eventualmente sustituidos con flúor y grupos ciano; o una sal fisiológicamente inofensiva de los mismos. También se describen los métodos de obtención de las sustancias de fórmula (1), los compuestos intermediarios a partir de los cuales se obtienen las sustancias de fórmula (1), los medicamentos que contienen dichas sustancias y el uso de las mismas para la preparación de un medicamento. Las sustancias de fórmula (1) pueden ser usadas específicamente para el tratamiento de enfermedades en las que una estimulación de los receptores nicotínicos de acetilcolina provocan una mejoría del cuadro clínico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10044905A DE10044905A1 (de) | 2000-09-12 | 2000-09-12 | (2-Azabicyclo[2.2.1]hept-7-yl)methanol-Derivate als nikontinische Acetylcholinrezeptor Agonisten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR034557A1 true AR034557A1 (es) | 2004-03-03 |
Family
ID=7655825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010104304A AR034557A1 (es) | 2000-09-12 | 2001-09-12 | Derivados de (2-azabiclo[2.2.1]hept-7-il)metanol como agonistas de receptores nicotinicos de acetilcolina |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7008955B2 (es) |
| EP (1) | EP1317430B1 (es) |
| JP (1) | JP2004509106A (es) |
| CN (1) | CN1455770A (es) |
| AR (1) | AR034557A1 (es) |
| AT (1) | ATE295835T1 (es) |
| AU (1) | AU2001285945A1 (es) |
| CA (1) | CA2421936A1 (es) |
| DE (2) | DE10044905A1 (es) |
| ES (1) | ES2240506T3 (es) |
| HU (1) | HUP0302971A2 (es) |
| MX (1) | MXPA03002076A (es) |
| PT (1) | PT1317430E (es) |
| WO (1) | WO2002022578A1 (es) |
| ZA (1) | ZA200302829B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10118551A1 (de) * | 2001-04-14 | 2002-10-17 | Merck Patent Gmbh | Nikotinische Acetylcholinrezeptor Liganden |
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| EP1480977A2 (en) * | 2002-02-15 | 2004-12-01 | PHARMACIA & UPJOHN COMPANY | Substituted aryl compounds for treatment of disease |
| BRPI0408815A (pt) * | 2003-03-28 | 2006-04-04 | Pharmacia & Upjohn Co Llc | moduladores alostéricos positivos do receptor nicotìnico da acetilcolina |
| ES2673016T3 (es) | 2008-11-19 | 2018-06-19 | Forum Pharmaceuticals Inc. | Tratamiento de los síntomas negativos de la esquizofrenia con (R)-7-cloro-N-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma |
| CN102802620A (zh) * | 2009-05-11 | 2012-11-28 | 英维沃医药有限公司 | 使用某种α-7烟酸受体与乙酰胆碱酯酶抑制剂结合治疗认知障碍 |
| EP3604302A1 (en) | 2010-05-17 | 2020-02-05 | Forum Pharmaceuticals Inc. | Preparation of crystalline forms of (r)-7-chloro-n-(quinuclidin-3-yl)benzo(b)thiophene-2-carboxamide hydrochloride monohydrate |
| EP3666272A1 (en) | 2012-05-08 | 2020-06-17 | Forum Pharmaceuticals Inc. | Use of encenicline in the treatment of cognitive impairment, alzheimer's disease, memory deficit |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9020051D0 (en) | 1990-09-13 | 1990-10-24 | Pfizer Ltd | Muscarinic receptor antagonists |
| US5817679A (en) | 1993-04-01 | 1998-10-06 | University Of Virginia | 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands |
| US6117889A (en) * | 1994-04-01 | 2000-09-12 | University Of Virginia | 7-Azabicyclo-[2.2.1]-heptane and -heptene derivatives as analgesics and anti-inflammatory agents |
| EP0978280A1 (en) | 1997-04-26 | 2000-02-09 | Sumitomo Pharmaceuticals Company, Limited | 2-azabicyclo compounds |
| GB9822945D0 (en) | 1998-10-20 | 1998-12-16 | Isis Innovations Ltd | Epibatidine analogues |
-
2000
- 2000-09-12 DE DE10044905A patent/DE10044905A1/de not_active Withdrawn
-
2001
- 2001-09-11 HU HU0302971A patent/HUP0302971A2/hu unknown
- 2001-09-11 ES ES01965274T patent/ES2240506T3/es not_active Expired - Lifetime
- 2001-09-11 CA CA002421936A patent/CA2421936A1/en not_active Abandoned
- 2001-09-11 JP JP2002526831A patent/JP2004509106A/ja active Pending
- 2001-09-11 EP EP01965274A patent/EP1317430B1/de not_active Expired - Lifetime
- 2001-09-11 PT PT01965274T patent/PT1317430E/pt unknown
- 2001-09-11 MX MXPA03002076A patent/MXPA03002076A/es not_active Application Discontinuation
- 2001-09-11 CN CN01815520A patent/CN1455770A/zh active Pending
- 2001-09-11 DE DE50106266T patent/DE50106266D1/de not_active Expired - Fee Related
- 2001-09-11 AU AU2001285945A patent/AU2001285945A1/en not_active Abandoned
- 2001-09-11 WO PCT/EP2001/010491 patent/WO2002022578A1/de not_active Ceased
- 2001-09-11 AT AT01965274T patent/ATE295835T1/de not_active IP Right Cessation
- 2001-09-11 US US10/380,064 patent/US7008955B2/en not_active Expired - Fee Related
- 2001-09-12 AR ARP010104304A patent/AR034557A1/es unknown
-
2003
- 2003-04-10 ZA ZA200302829A patent/ZA200302829B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001285945A1 (en) | 2002-03-26 |
| CN1455770A (zh) | 2003-11-12 |
| ATE295835T1 (de) | 2005-06-15 |
| HUP0302971A2 (hu) | 2003-12-29 |
| EP1317430B1 (de) | 2005-05-18 |
| JP2004509106A (ja) | 2004-03-25 |
| CA2421936A1 (en) | 2003-03-11 |
| WO2002022578A1 (de) | 2002-03-21 |
| MXPA03002076A (es) | 2003-06-24 |
| US20040039045A1 (en) | 2004-02-26 |
| DE10044905A1 (de) | 2002-03-21 |
| ES2240506T3 (es) | 2005-10-16 |
| DE50106266D1 (en) | 2005-06-23 |
| ZA200302829B (en) | 2004-08-13 |
| EP1317430A1 (de) | 2003-06-11 |
| US7008955B2 (en) | 2006-03-07 |
| PT1317430E (pt) | 2005-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR004219A1 (es) | Nuevos derivados de quinazolina, procedimientos para su preparacion, composiciones que los contienen y su uso en la preparacion de medicamentos,particularmente en el tratamiento de trastornos inflamatorios | |
| AR045595A1 (es) | Composiciones utiles como inhibidores de proteinas quinasas | |
| CO5590895A2 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos | |
| ES2084944T3 (es) | Amidas terapeuticas. | |
| AR033306A1 (es) | Compuestos | |
| KR960014121A (ko) | 아로일-피페리딘 유도체 | |
| AR037517A1 (es) | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria | |
| AR018204A1 (es) | METODO PARA LA PREPARACIOON DE CITALOPRAM , INTERMEDIARIO PARA LA PREPARACION DE CITALOPRAM Y EL USO DEL INTERMEDIARIO PARA LA PREPARACIoN DE CITALOPRAM | |
| KR890700125A (ko) | 신규 벤즈이미다졸 유도체, 그 제조방법 및 이 화합물을 함유하는 제약 조성물 | |
| DK164259C (da) | Farmaceutisk formulering til langsom frigivelse af den aktive bestanddel og fremgangsmaade til fremstilling af en saadan formulering | |
| ES2076147T3 (es) | Nuevos derivados de amina ciclicos, medicamento que contiene estos compuestos y procedimiento para su preparacion. | |
| AR030203A1 (es) | Derivados de carbamato de 2-(s)-hidroximutilina, composiciones farmaceuticas que los comprenden, procedimiento para prepararlos y 2(s), 11-dihidroxi protegida-mutilina como compuesto intermediario | |
| ES2011296B3 (es) | Derivados de benzo[b]tiofeno y benzo [b]furano carboxamidas, sus procedimientos de preparacion y los medicamentos que los contienen. | |
| ES2065324T3 (es) | N-(piridinil)-1h-indol-1-aminas, un procedimiento para su preparacion y su uso como medicamentos. | |
| AR032778A1 (es) | Benzimidazoles sustituidos, y su utilizacion para la preparacion de medicamento | |
| EA200200096A1 (ru) | Новые производные витамина d с циклическими субструктурами в боковых цепях, способ и промежуточные продукты для их получения и их применение для получения лекарственных средств | |
| CY1105387T1 (el) | Υποκατεστημενα παραγωγα 2-διαλκυλαμινοαλκυλοδιφαινθλιου | |
| ES2084339T3 (es) | Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central. | |
| AR040126A1 (es) | Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento | |
| AR034557A1 (es) | Derivados de (2-azabiclo[2.2.1]hept-7-il)metanol como agonistas de receptores nicotinicos de acetilcolina | |
| ES2063186T3 (es) | Derivados ftalinida, composicion farmaceutica y uso. | |
| AR027335A1 (es) | Compuestos de piperidina-4-sulfonamida, proceso de preparacion de los mismos, y composiciones farmaceuticas que los contienen | |
| ATE263166T1 (de) | Neue benzoxazole mit pde-hemmender wirkung | |
| AR018619A1 (es) | Derivados de 8-fenilxantina utiles como inhibidores de fosfoestearasa gmp ciclica (pdes), preparacion, composiciones farmaceuticas formuladas con dichosderivados y uso de dichos derivados para la fabricacion de medicamentos | |
| KR910004609A (ko) | 아미노케톤 유도체 및 그의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |